Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

KIMBERLY CLARK CORP (KMB)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $108.15 (close 2026-11-17); latest close $106.38 (2026-11-20), -1.6% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -31% · upside +27%

At $108.15, the market prices only +1.4% annual revenue growth for ten years at an 11.7% FCF margin, against -2.1% latest fiscal-year growth. That is a low bar, but the shares are not cheap on clean earnings: adjusted P/E is 38.0x while GAAP P/E is 20.1x, flattered by $1.55B of discontinued operations, 47% of net income. The Kenvue deal also adds shares and debt before the first combined print, so the risk and reward are not decisively skewed. PASS is the call: there is no base case, because the peers' P/E is GAAP and the company's GAAP P/E (20.1x) is more than 5% from the adjusted P/E the downside is on (38x), so a base at the peer multiple would sit on other earnings than the downside and upside. Downside is -31.8% to $73.71, on -10.0% earnings at a compressed P/E of 29.0x (today 38.0x). Upside is +25.0% to $135.19, on +25% earnings at today's P/E of 38x.

Key numbers

  • Share price: $106.38
  • Market cap: $65.28B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $16.57B
  • EV / EBITDA (TTM): 22.3x
  • P/E (TTM): 19.8x
  • FCF yield: 2.9%
  • Price / book: 22.27x
  • Earnings-quality flags (TTM): Discontinued operations $1.55B (47% of net income)
  • P/E, adjusted (TTM): 37.4x
  • EV / FCF (TTM): 35.9x
  • Revenue growth (latest fiscal year): -2.1%
  • ROIC (TTM): 22.2%
  • WACC: 5.5%
  • Economic profit spread: +16.8 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Kimberly-Clark makes and sells daily-need paper and nonwoven products under No. 1/No. 2 brands (Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, WypAll) in more than 175 countries, sold direct to supermarkets, mass merchandisers, drugstores, clubs and e-commerce, with Walmart alone about 16% of 2025 net sales from continuing operations. The business has been reshaped between the two annual reports: the FY2020 filing ran three product segments (Personal Care, Consumer Tissue, K-C Professional), while the FY2025 filing runs two geographic segments (North America, International Personal Care) after the International Family Care and Professional business was put into a Suzano joint venture and reported as discontinued operations, with a pending all-stock-and-cash acquisition of Kenvue signed November 2, 2025. Scale has shrunk on the top line: revenue was $19.14B in FY2020 and $16.45B in FY2025, with $16.57B on a TTM basis to September 30, 2026, and operating income $2.35B in FY2025 versus $3.24B in FY2020. Cash generation remains the core: operating cash flow $2.78B in FY2025 and $3.38B TTM against capex $1.14B and $1.44B respectively, while buybacks fell to $141.0M in FY2025 and $1.0M TTM from $1.00B in FY2024.

  2. ✓ 2. Competitive advantage

    The sources do not establish a durable competitive advantage: K-C competes in highly competitive domestic and international markets against branded and private-label products, and large retailers and e-tailers have significant bargaining power. Margin and cash-flow history shows scale and positive cash generation, but FY2025 and TTM to 2026-09-30 gross profit and operating income remain below FY2022 levels, and TTM net income is above pre-tax income so it is not an operating measure. Brand reputation is called critical, but the same filing stresses private-label, input-cost and pricing pass-through risks; no market-share or pricing-power data is given.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 sales fell to $4,134M from $4,150M, and operating profit fell to $516M from $621M as marketing, research and general expenses rose; nine-month sales and operating profit were up. Reported Q3 net income of $1,793M is not an operating result: $1,395M came from discontinued operations tied to the IFP sale gain. Cash rose to $1,874M, inventories to $1,579M, no buybacks in the nine months to Sep 2026, and the Oct 15 release kept FY2026 outlook with organic sales about 100 bps below category growth and adjusted operating profit mid-single-digit constant-currency growth. The supplemental risk factors focus on Kenvue integration, higher debt and dividend cash needs, and product-safety exposure.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans